| pubmed-article:16369009 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16369009 | lifeskim:mentions | umls-concept:C0017462 | lld:lifeskim |
| pubmed-article:16369009 | lifeskim:mentions | umls-concept:C0023206 | lld:lifeskim |
| pubmed-article:16369009 | lifeskim:mentions | umls-concept:C0023886 | lld:lifeskim |
| pubmed-article:16369009 | lifeskim:mentions | umls-concept:C0042210 | lld:lifeskim |
| pubmed-article:16369009 | lifeskim:mentions | umls-concept:C0014323 | lld:lifeskim |
| pubmed-article:16369009 | lifeskim:mentions | umls-concept:C1522673 | lld:lifeskim |
| pubmed-article:16369009 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:16369009 | pubmed:dateCreated | 2005-12-21 | lld:pubmed |
| pubmed-article:16369009 | pubmed:abstractText | The protozoan parasite Entamoeba histolytica causes invasive amoebiasis characterized by amoebic dysentery and liver abscesses (ALA). The E. histolytica galactose/N-acetyl-D-galactosamine-inhibitable lectin (Gal-lectin), an immunogenic surface molecule involved in colonization and invasion, is a promising vaccine candidate against amoebiasis. Gal-lectin is known to induce Th1 cytokines in macrophages and spleen cells in vitro, and a Th1 response is thought to be protective against ALA. In this study, we report the use of cytosine guanine oligodeoxynucleotide (CpG-ODN) as adjuvant to augment Th1 responses against Gal-lectin in the gerbil model of ALA. Gerbils were vaccinated intramuscularly with the native Gal-lectin plus CpG-ODN or a paired non-CpG control GpC-ODN, and control gerbils received CpG-ODN alone. One week after the last boost gerbils were challenged intrahepatically with 10(6) amoebae. Gerbils receiving CpG-ODN as adjuvant with Gal-lectin were completely protected against the development of ALA, whereas 50% of gerbils receiving GpC-ODN and Gal-lectin developed ALA and 85% of controls developed ALA. Stronger lymphoproliferation in response to the Gal-lectin and higher prechallenge titers of serum Gal-lectin-specific antibodies, capable of blocking amoebic adherence, were observed when CpG-ODN was used as adjuvant. Gerbils vaccinated with CpG-ODN and Gal-lectin also had significantly higher levels of gamma interferon, interleukin-12 (IL-12), and IL-2 mRNA than controls. These data indicate that CpG-ODN can enhance the Th1 responses, which improve the protective effects of Gal-lectin. This is the first report of the use of CpG as a potent Th1 adjuvant with Gal-lectin to increase protection against ALA formation. | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16369009 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16369009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16369009 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16369009 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:16369009 | pubmed:issn | 0019-9567 | lld:pubmed |
| pubmed-article:16369009 | pubmed:author | pubmed-author:ChadeeKrisK | lld:pubmed |
| pubmed-article:16369009 | pubmed:author | pubmed-author:KellerKathyK | lld:pubmed |
| pubmed-article:16369009 | pubmed:author | pubmed-author:IvoryCatherin... | lld:pubmed |
| pubmed-article:16369009 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16369009 | pubmed:volume | 74 | lld:pubmed |
| pubmed-article:16369009 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16369009 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16369009 | pubmed:pagination | 528-36 | lld:pubmed |
| pubmed-article:16369009 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:16369009 | pubmed:meshHeading | pubmed-meshheading:16369009... | lld:pubmed |
| pubmed-article:16369009 | pubmed:meshHeading | pubmed-meshheading:16369009... | lld:pubmed |
| pubmed-article:16369009 | pubmed:meshHeading | pubmed-meshheading:16369009... | lld:pubmed |
| pubmed-article:16369009 | pubmed:meshHeading | pubmed-meshheading:16369009... | lld:pubmed |
| pubmed-article:16369009 | pubmed:meshHeading | pubmed-meshheading:16369009... | lld:pubmed |
| pubmed-article:16369009 | pubmed:meshHeading | pubmed-meshheading:16369009... | lld:pubmed |
| pubmed-article:16369009 | pubmed:meshHeading | pubmed-meshheading:16369009... | lld:pubmed |
| pubmed-article:16369009 | pubmed:meshHeading | pubmed-meshheading:16369009... | lld:pubmed |
| pubmed-article:16369009 | pubmed:meshHeading | pubmed-meshheading:16369009... | lld:pubmed |
| pubmed-article:16369009 | pubmed:meshHeading | pubmed-meshheading:16369009... | lld:pubmed |
| pubmed-article:16369009 | pubmed:meshHeading | pubmed-meshheading:16369009... | lld:pubmed |
| pubmed-article:16369009 | pubmed:meshHeading | pubmed-meshheading:16369009... | lld:pubmed |
| pubmed-article:16369009 | pubmed:meshHeading | pubmed-meshheading:16369009... | lld:pubmed |
| pubmed-article:16369009 | pubmed:meshHeading | pubmed-meshheading:16369009... | lld:pubmed |
| pubmed-article:16369009 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16369009 | pubmed:articleTitle | CpG-oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica Gal-inhibitable lectin vaccine against amoebic liver abscess in gerbils. | lld:pubmed |
| pubmed-article:16369009 | pubmed:affiliation | Faculty of Medicine, Department of Microbiology and Infectious Diseases, University of Calgary Health Sciences Centre, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada. | lld:pubmed |
| pubmed-article:16369009 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16369009 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
